District of Columbia

Policy-wise, D.C. is clear but narrow. D.C. Law 23-268 permanently codified the Entheogenic Plant and Fungus Policy Act, and the code sections identify it as created by Initiative 81. The legislation’s operative focus is law-enforcement priority and a desire for cessation of prosecution, not creation of licensed services.###

That distinction drives access implications. Adults may face lower MPD priority for certain non-commercial entheogenic-plant and fungus conduct, but there is no verified District framework for legal commercial treatment centres, product manufacturing, or a local therapeutic licence system. Publication should therefore avoid language like “legal psilocybin therapy in D.C.”###

The primary official materials reviewed for this update do not verify a D.C.-based psychedelic clinical-research hub. That does not mean none exists; it means a professional Blossom page should not imply one without a verified registry or institutional source.###

Accordingly, D.C. should be framed as policy-relevant rather than research-dense on the evidence reviewed here. If a D.C. university, hospital or federal-adjacent institution is later added, it should be supported by a directly verified source.###

Implementation in D.C. is comparatively light because the law is limited in scope. The clearest verified machinery is MPD’s integration of Initiative 81 into relevant directive categories such as calls for service and drug-complaint handling. That is meaningful for enforcement practice, but far less elaborate than licensing, inspection, training or service-centre regulation.###

For stakeholders, that means operational uncertainty is less about provider rules and more about enforcement boundaries, federal exposure and the absence of a regulated local market. D.C. should be described as having a lowest-priority policing framework, not a therapeutic implementation apparatus.###

The District’s verified ecosystem is policy-led. Initiative 81 and MPD implementation materials make D.C. relevant to journalists, reform advocates and comparative policy researchers, but the official sources reviewed here do not establish a comparable regulated-services ecosystem.###

From an access perspective, the clearest lawful care channels remain ordinary ketamine/esketamine providers operating under conventional medical rules. That means D.C. is important in the conversation about deprioritisation and enforcement, while still limited on verified state-like access infrastructure.###

Over the next 12 to 24 months, the District is more likely to remain a policy-symbol jurisdiction than to become a full psychedelic-services market unless the Council separately enacts a licensing or regulatory regime. Nothing in the primary sources reviewed here supports describing such a regime as live today.###

The principal uncertainties are federal and institutional rather than local-administrative. Any future D.C. access story would likely require either new Council legislation, a verified research expansion, or wider federal movement, because Initiative 81 by itself does not generate a clinical delivery system.###